The specimens were routinely tested for infl uenza A and B viruses, respiratory syncytial virus, and parainfl uenza viruses 1, 2, and 3 by immunofl uorescence assay (Imagen; DakoCytomation, Trappes, France). Specimens positive for KIPyV or WUPyV were tested for adenoviruses; human bocavirus; human rhinoviruses; human metapneumovirus; human coronaviruses OC43, 229E, NL63, HKU1; and human PyVs BK and JC by using PCR methods (6) (7) (8) (9) (10) (11) . Total nucleic acid was extracted from 200 μL of NA, BAL, or stool specimens by using the EasyMag System (bio-Mérieux, Marcy l'Etoile, France). KIPyV was detected with an in-house real-time PCR assay targeting the VP1 gene. The primers and hydrolysis probe were designed by using Primer Express 3.0 software (Applied Biosystems, Foster City, CA, USA). The fi nal reaction volume was 25 μL and contained 12.5 pmol of SLKI-VP1s (5′-GGAAATACAGCTGCTCAGGAT-3′) and SLKI-VP1as (5′-CTTTGATACTTGAACCGCTTTCCTT-3′), 6.25 pmol of corresponding probe SLKI-VP1PR (5′-6FAM-C GTGACCCCACCCCTCATTACTGGTC-TAMRA-3′), 12.5 μL of TaqMan Universal Master Mix (Applied Biosystems), and 5 μL of DNA extract. The reaction was run on a 7500 Real-Time PCR System (Applied Biosystems). The specifi city of positive specimens was confi rmed by using PCR and nested PCR with primers POLVP1-39F/POLVP1-363R and POLVP1-118F/POLVP1-324R, as described (1) . The PCR products were then sequenced and compared with the previously described sequences from Sweden and Australia (GenBank accession nos. EF127906, EF127907, EF127908, EF520287, EF520288, and EF520289). WUPyV was detected by PCR as described (3) . PCR products with the expected molecular weights were sequenced by using primers AG0044 and AG0045 and compared to published sequences (GenBank accession nos. EF444550, EF444551, EF444552, EF444553, and EF444554) (3).